BTOG 2017 | Immunotherapy in second-line treatment of non-small cell lung cancer
Benjamin Besse, MD, PhD, Institut Gustave Roussy, Paris, France, provides an overview of the status of immunotherapies for second-line treatment of non-small cell lung cancer. There is a lot of debate in the oncology community as to whether PD-L1 testing should be an essential prerequisite for patient selection. Prof Besse highlights recent studies that showed a detrimental effect of immunotherapy relative to chemotherapy in a subset of PD-L1 negative patients, and that this should be taken into consideration despite the lack of clinical markers and biomarkers to identify these patients.
Recorded at the 2017 meeting of the British Thoracic Oncology Group (BTOG) in Dublin, Ireland.
Get great new content delivered to your inboxSign up